World-first community clinical trial for people who are dependent on cannabis!

The University of Sydney and NSW health are pioneering a phase III clinical trial using Sativex® (a cannabinoid replacement therapy) for the management of treatment-resistant cannabis patients. The trial involves the use of an oral spray called Sativex (which contains 2.7mg THC and 2.5mg CBD) or a placebo to assess the efficacy for treating cannabis dependent patients who have not previously responded to conventional treatment.

For further information regarding the trial, visit: and complete the Sativex survey or call on: 02 9332 8794